Neuroscience
Our focus in neuroscience
At Johnson & Johnson Innovative Medicine (J&J) UK, our goal is to enhance the quality of life for patients affected by nervous system disorders in the UK.
We are dedicated to developing targeted and impactful treatment options that alleviate the burden of neurological conditions, supported by an evolving pipeline that strengthens our innovative products.
Through our in-house discovery, strategic partnerships and acquisitions, we are transforming our approach to understanding and treating these complex conditions.
We are dedicated to developing targeted and impactful treatment options that alleviate the burden of neurological conditions, supported by an evolving pipeline that strengthens our innovative products.
Through our in-house discovery, strategic partnerships and acquisitions, we are transforming our approach to understanding and treating these complex conditions.
Our legacy in neuroscience
At J&J we are committed to advancing the field of neuroscience through continuous innovation and collaboration. Building on a legacy of over 70 years in neuroscience leadership, we are driving cutting-edge research in biomarkers, data science, and clinical trials to deepen our understanding of the underlying biology of neurological disorders.
In the UK, we also aim to support the medical community through medical education, helping to ensure healthcare practitioners are equipped with the latest advancements to improve patient care.
In the UK, we also aim to support the medical community through medical education, helping to ensure healthcare practitioners are equipped with the latest advancements to improve patient care.
70
Years of innovation in neuroscience
100+
UK medical education meetings to support healthcare practitioners with bringing the latest medical advancements to patients
Patient-centered research and collaboration
At J&J, we are inspired by the patients and caregivers we serve, placing them at the heart of everything we do. Health is personal, and we take neurological health personally.
We understand the diversity of individuals affected by neurological and neuropsychiatric conditions, which is why we are committed to a tailored approach in our research and product development. Rather than relying on a “one-size-fits-all” model, we focus on addressing the unique needs of each patient, ensuring our therapies and support initiatives align with the real, unmet needs of those we aim to help.
Our success in neuroscience is also deeply rooted in collaboration. By fostering strong partnerships with leading experts, healthcare bodies, and government organisations, we aim to accelerate access to care, eliminate barriers to diagnosis, and deliver practical, transformative solutions for patients in the UK and worldwide.
We understand the diversity of individuals affected by neurological and neuropsychiatric conditions, which is why we are committed to a tailored approach in our research and product development. Rather than relying on a “one-size-fits-all” model, we focus on addressing the unique needs of each patient, ensuring our therapies and support initiatives align with the real, unmet needs of those we aim to help.
Our success in neuroscience is also deeply rooted in collaboration. By fostering strong partnerships with leading experts, healthcare bodies, and government organisations, we aim to accelerate access to care, eliminate barriers to diagnosis, and deliver practical, transformative solutions for patients in the UK and worldwide.
Our vision in neuroscience
At J&J, our focus is on understanding the biological causes of neurological disorders to develop more effective treatments. Our continued commitment to innovation aims to improve outcomes for those living with neurological conditions.
16.5M
People impacted in the UK1
1 in 6
People in the UK living with a neurological condition1
With over 70 years of expertise in neuroscience, Johnson & Johnson remains dedicated to advancing research and innovation in neurodegenerative and autoimmune disorders. Our ongoing commitment to understanding complex neurological conditions drives us to explore new treatment possibilities, ensuring we are shaping the future of care for patients today and in the years to come.”
Naomi Cragg
Business Unit Director, Johnson & Johnson Innovative Medicine, UK.
We are committed to partnering with those whose innovative thinking will bring new and creative solutions to the field of medicine
References
1: The Neurological Alliance. Neuro Numbers 2019. March 2019. Available at: https://www.neural.org.uk/wp-content/uploads/2021/04/neuro-numbers-2019-1.pdf
This link will take you to a website which is not owned or controlled by Johnson & Johnson Innovative Medicine UK and where our privacy policy does not apply. Click below to continue.
. Last accessed: November 2024.
You are now leaving Johnson & Johnson Innovative Medicine UK
CP-486605 | November 2024